Welcome to our dedicated page for Quanterix news (Ticker: QTRX), a resource for investors and traders seeking the latest updates and insights on Quanterix stock.
Quanterix Corporation (NASDAQ: QTRX) generates news that spans scientific breakthroughs, clinical research, corporate developments, and financial performance, all centered on its ultra-sensitive Simoa biomarker detection technology and spatial biology capabilities. As a life sciences company active in testing laboratories and professional scientific services, Quanterix regularly reports on studies, collaborations, and product launches that affect disease research and diagnostics.
Investors and researchers following QTRX news will see coverage of peer‑reviewed studies that rely on Simoa assays, such as large population-based analyses of Alzheimer’s Disease Neuropathological Changes using p‑Tau 217, and multiple sclerosis research that combines GFAP and NfL biomarkers for personalized monitoring. These articles illustrate how Quanterix assays and reference databases are applied in real-world clinical and epidemiological settings.
The company also issues updates on new assay launches and platform enhancements, including commercial introductions of p‑Tau 205 and p‑Tau 212 assays for Alzheimer’s research, and developments at the Quanterix Accelerator Laboratory, which supports clinical testing and global clinical trials. News items may highlight regulatory milestones, such as clinical laboratory permits and medical device registrations for specific assay kits in various markets.
From a corporate and capital markets perspective, Quanterix news includes quarterly financial results, non‑GAAP performance metrics, and commentary on integration progress following its acquisition of Akoya Biosciences. Filings and press releases discuss cost synergies, revenue composition across product and service lines, and governance changes such as cooperation agreements with shareholders and Board structure updates.
This QTRX news page brings together these updates so readers can track scientific publications, diagnostic advancements, spatial biology integration, and financial disclosures in one place.
Quanterix Corporation (NASDAQ: QTRX) has announced the validation of a new CLIA blood test to quantitatively measure neurofilament light chain (NfL) levels in serum. This test aids in assessing neurodegenerative conditions and neuronal damage. NfL is a crucial biomarker for various neurological disorders, and the Simoa NfL test is widely recognized for its clinical relevance. The FDA previously granted Breakthrough Device designation for this test in relation to multiple sclerosis. This launch aims to enhance clinical diagnostics and support future therapeutic trials.
Quanterix Corporation (NASDAQ: QTRX) announced that CEO Masoud Toloue will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, Jan. 12, 2023, at 12 p.m. PST. The presentation will be accessible to attendees and the public via a live audio webcast. Quanterix will also hold one-on-one meetings with institutional investors during the event. Replays of the webcast will be available for a limited time afterward. Quanterix specializes in ultrasensitive biomarker detection, enabling significant advancements in various disease research.
Quanterix Corporation (NASDAQ: QTRX) announced the role of its ultrasensitive Simoa technology in advancing clinical trials for Alzheimer’s disease (AD), presented at the 15th Clinical Trials on Alzheimer's Disease conference in San Francisco. Eisai and Biogen showcased Phase 3 trial results for lecanemab, highlighting biomarker engagement. Additional data from Eli Lilly and Janssen emphasized plasma biomarker utility. Quanterix aims to support future AD therapeutic trials with innovative testing tools, including FDA-designated Breakthrough Devices expected in 2023.
Quanterix Corporation (NASDAQ: QTRX) will participate in the 15th Clinical Trials on Alzheimer's Disease (CTAD) from November 29 to December 2, 2022, in San Francisco. CEO Masoud Toloue is set to present on the advantages of blood-based biomarkers such as pTau-181 and pTau-217 over traditional PET scans for clinical trial efficiency and patient monitoring. These biomarkers have shown promise in Phase III trials, facilitating the design of effective Alzheimer’s disease treatments. The conference aims to accelerate collaboration among leaders in Alzheimer’s research.
Quanterix Corporation (NASDAQ: QTRX) announced that President and CEO Masoud Toloue and CFO Michael Doyle will present at the CG MedTech, Diagnostics and Digital Health & Services Forum on November 17, 2022, at 4:30 p.m. EST in Boston, MA. They will engage in one-on-one and group meetings with institutional investors on the same day. A live webcast of the presentation will be available on Quanterix's Investor website, with replays accessible for 90 days. Quanterix specializes in ultrasensitive biomarker detection aimed at advancing research in various medical fields.
Quanterix Corporation (NASDAQ: QTRX) reported flat revenue of $26.6M for Q3 2022 compared to Q3 2021, up 13% from Q2 2022. Pro-forma gross margin was 35%, down 1470 bps year-over-year but up 670 bps quarter-over-quarter. The company is progressing in the Bio-Hermes trial and received funding from the Alzheimer’s Drug Discovery Foundation to advance Alzheimer's diagnostic tests. However, the restructuring has incurred significant charges, including $8.2M in goodwill impairment. Q3 net loss reached $35.1M, a substantial increase from $15.7M in Q3 2021.
Quanterix Corporation (NASDAQ: QTRX) announced it will hold a conference call on November 8, 2022, at 4:30 PM ET, to discuss its third quarter 2022 financial results. The call will feature President and CEO Masoud Toloue and CFO Michael Doyle. A press release detailing the earnings will be distributed before the call and available on the company’s website.
Quanterix specializes in ultrasensitive biomarker detection, providing significant advancements in various medical fields.
Quanterix Corporation (NASDAQ: QTRX) announces the resignation of Executive Chairman E. Kevin Hrusovsky, who has led the company since June 2014. Martin D. Madaus, previously serving as Executive Chairman and CEO, is appointed as the new Chairman of the Board. Hrusovsky, who played a pivotal role in Quanterix's growth into a leading biomarker detection firm, emphasized the need for board evolution to support future growth. The transition follows a leadership succession plan, with an optimistic outlook on the company's future developments and market position.
Quanterix Corporation (NASDAQ: QTRX) reported a Q2 2022 total revenue of $23.5M, down 7.4% from $25.4M in Q2 2021. Product revenue fell by 20.8% to $14.8M, while service and other revenue increased 51.3% to $8.5M. The gross margin declined to 37.1% from 54.7%, primarily due to assay quality challenges. The company is implementing a strategic restructuring plan, including a $10M charge and a reduction in workforce by 130 employees, aiming for $25M in annual savings. FY2022 revenue is expected to remain flat with a plan to return to double-digit growth by 2024.
Quanterix Corporation (NASDAQ: QTRX) announced that CEO Masoud Toloue will present at the Canaccord Genuity 42nd Annual Growth Conference on August 10, 2022, at 1:30 p.m. ET in Boston, MA. He will also hold one-on-one and group meetings with institutional investors. A live webcast of the presentation will be available on the Quanterix website, with replays accessible for 90 days post-conference. Quanterix focuses on digitizing biomarker analysis to enhance disease detection and treatment across various therapeutic areas.